This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Koretz, R. L. Search for Related Content PubMed PubMed Citation Articles by Koretz, R. L. Social Bookmarking                         What's this?

Probiotics, Critical Illness, and Methodologic Bias

From the Department of Medicine, Olive View-UCLA Medical Center, Sylmar, California.

Correspondence: Address correspondence to: Ronald L. Koretz, MD, Department of Medicine, Olive View-UCLA Medical Center, 14445 Olive View Drive, Sylmar, CA 91342; e-mail: rkoretz{at}msn.com.

It has been proposed that probiotics can favorably influence the course of critically ill patients. To address this question, a limited systematic review was undertaken (MEDLINE search for articles published in English) to identify randomized, controlled trials that compared a group of critically ill patients taking probiotics with a group that did not. Ten such trials, mostly with high risks of methodologic bias, were identified. When the data were combined, the probiotics did not appear to influence mortality or duration of hospitalization. However, the recipients of the probiotics had fewer infectious episodes (absolute risk difference-21%). This effect was seen particularly in trials employing one combination of probiotic agents (Pediococcus pentosaceus, Leuconostoc mesenteroides, Lactobacillus paracasei, Lactobacillus plantarum). Unfortunately, this effect may be overly optimistic, as methodologic shortcomings could have introduced biases into the trials. Three trials of patients with severe acute pancreatitis were not included in this primary analysis because not all of the patients were in the intensive care unit. The largest of these, and the one with the lowest risk of bias, demonstrated that probiotics increased mortality, in part because of the precipitation of ischemic bowel disease (in patients who were also receiving postpyloric enteral nutrition infusions). Probiotics also appeared to reduce the incidence of antibiotic-associated diarrhea in hospitalized patients, although these trials did not specifically focus only on those who were critically ill. In summary, it is not clear that probiotics are beneficial (and they may even be harmful) in the critically ill patient group.

Key Words: critical illness • probiotics • randomized controlled trials as topic • bias

Nutrition in Clinical Practice, Vol. 24, No. 1, 45-49 (2009)
DOI: 10.1177/0884533608329296


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?